ArticleIn vivo (Athens, Greece)
Association Between Urolithiasis and Hidradenitis Suppurativa: A Retrospective Cohort Study.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimHidradenitis suppurativa (HS) is a chronic inflammatory skin disorder associated with systemic comorbidities. Its potential link with urolithiasis, a common urological disease, remains unclear. PATIENTS AND
methodsWe conducted a multicenter, retrospective cohort study using the TriNetX US Collaborative Network. Adults ≥18 years with HS diagnoses and more than two visits between 2005 and 2018 were identified and matched 1:1 with non-HS controls using propensity scores. Patients with prior urolithiasis or malignancy were excluded. The final analytic cohort included 79,567 patients with HS and 79,567 controls. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. Sensitivity analyses applied alternative definitions, wash-out periods, and follow-up durations. Comparator groups included psoriasis, rosacea, and androgenic alopecia. Stratified analyses were performed by age and sex.
resultsHS was associated with an increased risk of urolithiasis in 15-year follow-up (HR=1.334, 95% CI=1.260-1.413). This association persisted across sensitivity analyses. Comparisons with psoriasis, rosacea, and androgenic alopecia also demonstrated significantly elevated risks (HRs ranging from 1.247 to 1.296). Stratified analyses showed consistent results in both sexes (males: HR=1.340, 95% CI=1.202-1.493; females: HR=1.326, 95% CI=1.214-1.417) and age groups (18-64 years: HR=1.317, 95% CI=1.237-1.402; ≥65 years: HR=1.308, 95% CI=1.160-1.475). Site-specific analyses demonstrated increased risks for renal, ureteric, and lower urinary tract calculi.
conclusionHS is associated with elevated risk of urolithiasis, consistent across analytic models and subgroups. These findings highlight the existence of overlapping inflammatory pathways and underscore the importance of renal monitoring in HS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.